BioPharma DiveOriginal article
GSK shelves cough drug acquired in $2B deal
Phase 3negativecamlipixantNegative
AI Analysis
Summary
GSK discontinued development of camlipixant, a cough drug acquired for $2 billion, following mixed Phase 3 trial results. The failure marks the third cough drug from its class to be shelved.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Mixed Phase 3 data prompted GSK to cease development
Importance:7/10
Sentiment:
-0.80
drug_failurephase_3_negativedevelopment_stoppedcough_treatmentacquisition_loss
Related Companies
Read the original article
Published by BioPharma Dive on July 17, 2026 1:21 PM